аЯрЁБс>ўџ KMўџџџJџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџьЅС{` №П<6bjbjюFюF .HŒ,Œ,<.џџџџџџЄЄЄЄЄЄЄЄИРРРРм$ИAЖ        РТТТТТТ$їh_шцЄ     цЄЄ  ћppp  Є Є Рp РppЄЄp   t‘ЈiМХР pР0ApG FGpGЄpP  p     ццf   A    ИИИD ќФИИИќИИИЄЄЄЄЄЄџџџџ Sympathomimetics, Antihistamines, and EENT Products Sympathomimetics Receptors There are four major sympathetic receptors: alpha-1, alpha-2, beta-1, and beta-2. The response of an organ depends on the specificity of the agonist/antagonist at a given receptor, the absolute number of receptors in that organ or organ system, and the ratio of receptors. Alpha-1 receptors are the primary receptors. Stimulation here causes smooth muscle contraction, vasoconstriction, decrease in mucous membrane secretion, and used to control blood flow. Beta-1 is used in some application of cardiac stimulation. Beta-2 is used for smooth muscle relaxation (asthma treatment). Common Uses Sympathomimetics are mixed acting adrenergic agonists. They combine with the receptor and produce a response. They act by causing NE release or block its reuptake. Hemorrhage – sympathomimetics activate the alpha-1 receptor. Epinephrine is used to control superficial vasoconstriction, controlling capillary bleeding. It is commonly used in nasal surgery. With Local Anesthetics – EPI acts on the alpha-1 receptor to cause local vasoconstriction. Blood flow is decreased, which slows absorption and localizes the affect of the anesthetic. Nasal Decongestants – alpha agonists are applied locally or orally. They constrict swollen (edematous) vessels and tissue. This relieves mucosal congestion. Anaphylaxis (acute allergic reaction) – EPI acts on alpha-1 to relieve swelling; beta-2 to relax constricted bronchial smooth muscle; and beta-1 for some cardiac stimulation (use with caution) Hypotension (Hypotensive crisis) – alpha agonists, like dopamine, have a pressor action. It increases blood pressure via vasoconstriction. Caution should be used because it can cause ischemia in the extremities or organs with prolonged administration. Withdrawal should be done so in a slowly tapered manner to prevent recurrence. Nasal Preparations Topical – used a vasoconstrictor. Oxymetazolone (afrin, Dristan) has a long duration of action, so it does not need to be re-administered often. Phenylephrine (neo-synephrine) has a shorter duration of action so it needs to be given often. These will relieve nasal congestion associated with the common cold, allergic rhinitis, and sinusitis. Sprays – preferred in adults. Provide better coverage of nasal mucosa. Easy self-administration. Drops – preferred in children. Their nostrils are smaller, so they are easily administered by adults. Use the lowest strength in children and should not be used in those under two years old. Saline drops can initially be used for children. Systemic absorption is minimal. There is slightly more absorption with drops due to swallowing capabilities. ADRs include local irritation (burning, stinging, sneezing, dryness), rhinitis medicamentosa (rebound), contradiction with MAO-Is, and increased heart rate. Rhinitis medicamentosa can be caused by both oxymetazolone and phenylephrine. If the patient uses these drugs for over 3-4 days, there is desensitization of the receptors so the patient does not get relief. As a result, the patient takes more of the drug on a daily basis. Rebound can be worse than the original congestion. Ophthalmic Ophthalmic sympathomimetics include oxymetazolone (Ocuclear), phenylephrine (Relief), Tetrahydrozaline (Visine), and Naphazoline (Clear eyes, Naphcon). Cautions should be taken when taken these drugs. If the patient has contact lenses, the drops need to be compatible. They are contraindicated in narrow angle glaucoma. There is a greater chance of systemic absorption with eye drops due to the relatively high concentration of medication contained in the solution. The drug is absorbed directly into the tear duct. To lessen the absorption, the patient should be instructed to press on the tear duct when instilling the eye drop. Systemic – Oral Systemic sympathomimetics are structurally related to amphetamine. They include Pseudoephedrine (isomer of ephedrine, Sudafed), Ephedrine (appetite suppressant, Ma Huang), phenylpropanolamine (off the market), and phenylephrine. These drugs are available as single agents, such as Sudafed. Can also be found as combo agents with anti-histamine (with brompheniramine in Dimetapp), APAP, Ibuprofen, and anti-tussive. A combination of all of the above comprises “complete cold” formulas. ADRs include greater systemic effects, CNS stimulation – a prominent aspect of amphetamines (indirect acting), and a tolerance to stimulant properties, leading to drug dependence, especially with amphetamines. Histamine Histamine is produced primarily by mast cells and basophils. It is abundant in the skin, GI tract, and respiratory tract. In the GI tract, paracrine cells in the fundus (lining) stimulate gastric secretion by parietal cells. In the CNS, it is a neurotransmitter. Histamine is formed by the decarboxylation of histadine. It is released from the mast cells by IgE. This action is blocked with cromolyn NA. Mast cell degranulation can be caused by bacterial toxins and drugs (morphine and tubocurarine). A result is flushing and vasodilation when these drugs are given. The release of histamine is a primitive reflex and a protective mechanism. It provides the following: vasodilation, decreases blood pressure due to relaxation of arteriolar smooth muscles and venules, resulting in hypotension; increased vascular permeability, promoting fluid and plasma out of the blood into the extracellular spaces, leading to edema; tachycardia and increased contractility in the heart; bronchoconstriction in the lungs because the body is trying to decrease the amount of allergens entering the lungs. Histamine Receptors There are three histamine receptors; H1, H2, and H3 H1 Histamine receptor – activated in allergic reactions. Causes dermatitis, rhinitis, and conjunctivitis. Activation in the skin and mucous membranes causes vasodilation, increased vascular permeability, erythema, congestion, edema, and inflammation. This receptor is seen in the mucocutaneous nerves, which can lead to pruritis and cough. Histamine in circulation decreases blood pressure and causes anaphylactic shock. H2 Histamine receptor – found in the GI tract. Involved in GI acid secretions. Activated in allergic reactions. H1 and H2 blockers may be used in combo for some allergic reactions (Diphenhydramine and famotidine). H2 receptors are also found in the heart and when activated increase heart rate and contractility. H3 Histamine receptors – found on presynaptic nerve terminal. Similar to alpha-2 Antihistamines The H1 receptor antagonists block the actions of histamine by competitive inhibition at the receptor site. Most are capable of crossing the BBB and entering the CNS, causing sedation. These antihistamines have many other effects not due to the histamine receptor. Their chemical structure is similar to other endogenous agents and so they are capable of combining with other receptors in the body to produce a variety of side effects. Some may be undesirable or desirable because we can utilize their effect. Antihistamines are used in the treatment of allergies and motion sickness. They also have an anti-nausea and anti-emetic property because they inhibit the central CTZ (phenothiazines). They cause sedation so they are useful as sleep aids, like Diphenhydramine. Also possess anti-cholinergic effects by blocking muscarinic receptors, causing dry-wide eyes. Block alpha-1 receptors to cause an adrenergic blockade, causing orthostatic hypotension. EENT Anti-histamines are divided into first and second generation. First Generation (*) – used for seasonal or allergic rhinitis. First generation antihistamines are non-selective, so they bind to all H receptors. They have more ADRs. They bind to muscarinic and adrenergic receptors and cross the BBB easier, leading to sedation. Akylamines (*) – include crompheniramine (Dimetapp), Chlorpheniramine (Chlortrimeton), and Triprolidine (in Actifed), which causes the least amount of sedation and may even cause CNS stimulation Ethanolamonies (*) – include clemastine (Tavist) and Diphenhydramine (Benadryl), which are the most sedating and have anticholinergic effects Ethylenediamines (*) – include tripelennamine (Pyrabenzamine), which doesn’t cause much sedation Piperazines – include Meclizine (Antivert) for dizziness and inner ear imbalances; hydroxyzine (Vistaril, Atarax), which is the most sedating Phenothiazines – include Promethazine (Phenergan) (*), which is the most sedating and has anticholinergic effects Piperidines – include cyproheptadine (Periactin) which is used for GI effects, slowing peristalsis and is an anti-emetic. ADRs for first generation antihistamines include: sedation is the most common; may get paradoxical excitation in children and infants; atropine-like ADRs (anti-SLUD), like dry mouth, blurred vision, tachycardia, and urinary retention; anticholinergic toxicity in the manifestation of an overdose. Physostigmine, a cholinesterase inhibitor, should be administered in this case. Second Generation (*) – used for seasonal or allergic rhinitis Second generation antihistamines are peripherally receptive (outside the CNS), so they are non-sedating. They are only non-sedating when used in the appropriate dose. Piperidines (*) – include loratadine (Claritin). When Claritin is combined with pseudoephedrine, we get Claritin-D. Desloritadine (Clarinex) is a primary metabolite and may be more effective. Fexofenadine (Allegra) is a prescription drug and when combined with pseudoephedrine results in Allegra-D, which is believe to be the least sedating antihistamine. Piperazines (*) – includes Cetirizine (Zyrtec), which has more sedation than others because of the similarity in structure to first generation antihistamines The second generation’s advantage over the first generation is that they are relatively specific for the H1 receptor and therefore have little or no sedative activity. However, there are significant drug interactions with many antifungals (azoles) and most macrolides, causing lethal ventricular tachycardia (torsades de pointes). This has resulted in 2 drugs being removed from the market – Atemizole (Hismanal) and terfenadine (seldane) Second generation is recommended as the first line for patients who are prone to ADRs, like the elderly, CNS disorders, cardiac disorders, and people who overuse medications. Antihistamines are more effective in preventing histamine-mediated effects than reversing these effects. They are most effective when taken 1-2 hours prior to anticipated exposure of the offending allergen. They are well-absorbed orally, have a large Vd, and undergo liver metabolism. Topical Topical antihistamines are also considered second generation. Levocabastine (Livostin)* are eye drops. Azelastine (Astelin) is a nasal spray. Olopatadine (Patanol) are eye drops, as well as a mast cell stabilizer and antihistamine. Miscellaneous Cromolyn* stabilizes mast cell membranes and thereby prevents degranulation and release of histamine. It is found in Crolom (eye drops) and Nasalcrom (nasal spray). Montelukast (Singulair) is used for seasonal allergic rhinitis in adults and children over 2 years old. It is a leukotriene receptor antagonist. It is a potent inhibitor of the CYP450 system, blocking the metabolism of coumadin and phenytoin, resulting in more ADRs like headache, URI, and nausea. Other Agents for Rhinitis Intranasal steroids are very efficacious and are good if the patient also has asthma. There are less systemic ADRs but have a slower onset to relieve symptoms (2-3 weeks). Saline nasal preps and Ipratropium nasal spray (Atrovent-nasal) are also used. 34GQ ž Ћ S ^   / б х o p q — 3?@V‚ƒ˜ Лк+JѕќY_yя=[\]tŠЌЅІВзK12C•*љђљэщтэщнщйдйдйщйдйдйдйЭэнщЦщЦщнщнщТйТйщйдйЛйЭэйЛЗАэЗЉЗАэЂ˜Ђh4G1hТPљ5>* hТPљ5>* hhє56 hhєhhєhhє h m56hВ / hГi56 h mh m h m5h m hГi5 hГihГihГi hГi>* h ю5>* hГi5>*<45FGQd  ž Ÿ Ћ R S   а б p q 23ƒ„—˜єѕXYN§§§§§§§§§§§§§§§§§§§§§§§§§§§§§<6§NO\ІЇВK23C*-R_`tЉЊS T ‘!у!ф!х!ц!§§§§§§§§§§§§§§§§§§§§§§§іі§§§Є№gdЁ1шQ^_tЊРT j !.!‘!Ј!т!у!ф!х!ц!ѕ!і!s$Ђ$Б$я$%Н%П%Р%Ф%Щ% &&'"'1'l'Œ'к'л'м'я'ё'љ'-(k(€(њіђыцђсђсђкђсђгђЫЦМЕђБЊБЊБЊЃž™Б”БŒБЊ…Б|w…| hU-њ5 hU-њ6hU-њ hU-њ56h„зh„з6 h„з5 hЁ1ш>* h„з>* h„зhЁ1ш h„з56h„з hГi5>*h4G1h4G15>* h4G1>*hЁ1шhЁ1ш5 hЁ1шhЁ1ш hЁ1ш56 hЁ1ш5 hТPљ>* hhєhhєhЁ1шhhє hhє5.ц!і!ј#Н%Р%С%Т%У%Ф%Щ%& &H&''л'м'j(k(Ь(Э([)\)Ю)Я)I*J*Х+Ц+,§§§§§§§§§§§§§§§§§§§§§§§§§§§§§€(‚(Š(Њ(Э(й(л(у(ј( )>)\)k)m)u)“)Я)н)х)*Ц+м+Џ,П,Щ,о,-"-%->-r-‰-в-м-.'.2.G.A0p0q0C2D2E2M22Ї2З2Ь2п2ѕ2:3;3J3K3S3U3С3 4A4B4 5;5P5ъ5§56*6;6<6њіяіъњіяіяіъњіяіъіяіњіъіяіяіупупупкпупуіпгіЮпупупупгЩпСупупНпЖБпБпупг h)_€5 h)_€5>*hзKh)_€h)_€5 h4G1>* hГi>* h)_€h)_€ h)_€6h)_€ h)_€56 hU-њ6 hU-њ56hU-њ hU-њ5E,Ў,Џ,..Е.Ж.q0#1$1D2E2M2;3<3J3ђ35 5;5<6§§§§§§§§§§§§§§§§§§§§,1hАа/ Ар=!А"А# $ %ААаАа а†œ@@ёџ@ NormalCJ_HaJmH sH tH DA@ђџЁD Default Paragraph FontRiѓџГR  Table Normalі4ж l4жaі (kєџС(No List<.Hџџџџ45FGQdžŸЋRSабpq23ƒ„—˜єѕX Y N O \ І Ї В K 23C*-R_`tЉЊST‘уфхціјНРСТУФЩ Hлмj k Ь Э [!\!Ю!Я!I"J"Х#Ц#$Ў$Џ$&&Е&Ж&q(#)$)D*E*M*;+<+J+ђ+- -;->.˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€N O І Ї 23_`хц>.{ˆ0 XЁˆyˆ0 €{ˆ0 €yˆ0€{ˆ0 €yˆ0 €{ˆ0 €yˆ0€yˆ0€{ˆ0€yˆ0€{ˆ00€yˆ0€{ˆ0Ф&Ё€(<6 "Nц!,<6!#<6>.>.%)3)H)C*E*E*L*:+I+;.>.>.х ГiзKВ /4G1б"e m)_€,0›„зЁ1ш юhєТPљU-њџ@€,,0.с**,,<.P@џџUnknownџџџџџџџџџџџџG‡z €џTimes New Roman5€Symbol3& ‡z €џArial"ёˆ№аh ƒ™Іљ’™ƒцV'SцV'S$№ЅРДДr4%.%.2ƒQ№HX)№џ?фџџџџџџџџџџџџџџџџџџџџџГi2џџ3Sympathomimetics, Antihistamines, and EENT ProductsInformation TechnologyInformation Technologyўџр…ŸђљOhЋ‘+'Гй0И˜др ( HT t € Œ˜ ЈАф4Sympathomimetics, Antihistamines, and EENT ProductsInformation TechnologyNormalInformation Technology4Microsoft Office Word@вьL@ійђиКХ@.†šiМХцV'ўџеЭеœ.“—+,љЎ00 hp˜ Ј АИРШ а фSt John's UniversityS%.G 4Sympathomimetics, Antihistamines, and EENT Products Title  !"#$ўџџџ&'()*+,ўџџџ./0123456789ўџџџ;<=>?@AўџџџCDEFGHIўџџџ§џџџLўџџџўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџ РF0 АЈiМХN€Data џџџџџџџџџџџџ%1Tableџџџџ-GWordDocumentџџџџ.HSummaryInformation(џџџџџџџџџџџџ:DocumentSummaryInformation8џџџџџџџџBCompObjџџџџџџџџџџџџqџџџџџџџџџџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџ џџџџ РFMicrosoft Office Word Document MSWordDocWord.Document.8є9Вq